Datamonitor's Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.

Scope of the Report

* Contains an executive summary and data on value and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Covers Global, European, Asia-Pacific & 11 individual country markets

* Includes a five-year forecast of the industry

Highlights

The global pharmaceuticals market has demonstrated consistently strong growth patterns in the last five years.

The leading revenue source for the global pharmaceuticals market is the sale of cardiovascular drugs.

The last five years have produced turbulent times for big pharmaceutical firms. Blockbuster drug patent expirations and subsequent competition from pharmaceutical generics have been detrimental to market growth.

Why you should buy this report:

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Definition

The global pharmaceuticals market has demonstrated consistently strong growth patterns in the last five years. Market expansion was buoyed up by continued good growth in the US.

The global pharmaceuticals market generated total revenues of $534.8 billion in 2005, this representing a compound annual growth rate (CAGR) of 7.7% for the five-year period spanning 2001-2005. In comparison, the European pharmaceuticals market generated total revenues of $150.5 billion in 2005, this equates to a CAGR of 6% for the same period, while the US market had a value of $285.6 billion in 2005, having grown with a CAGR of nearly 10% during the 2001-2005 period.

The leading revenue source for the global pharmaceuticals market is the sale of cardiovascular drugs, which generated total revenues of $107.2 billion in 2005, equivalent to 20% of the overall market value. In comparison, the central nervous system sector was worth $91.1 billion, which represented a 17% share of the market's value.

Looking forward, the market is forecast to decelerate its current performance slightly, with an anticipated CAGR of 7.5% for the period 2005-2010 expected to drive the market to a value of $767.2 billion by the end of 2010. In comparison, the European market is also expected to decelerate its current performance, with an anticipated CAGR of 5.5% expected to drive the market to a value of $196.5 billion by 2010.